Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present at two upcoming medical meetings in September 2022. Details for the presentations are as follows:
| MDS 2022 International Congress of Parkinson’s Disease and Movement Disorders | |
| Abstract #: | 1007 |
| Poster Title: | GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase shows evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease |
| Date/time: | Saturday, September 17, 2022 at 1:00 PM CEST |
| Location: | Madrid Marriott Auditorium Hotel & Conference Center |
| Presentation Station: 8 | |
| Presenter: | Beatriz Calvo-Flores Guzman, Ph.D., Gain Therapeutics |
| Shaare Zedek Medical Center GBA-PD Symposium | |
| Session: | Disease-Modifying Strategies: New Concepts and Innovative Clinical Trials |
| Presentation: | Non-inhibitory Chaperones for GBA-PD |
| Date/time: | Thursday, September 22, 2022 at 3:05 PM EEST |
| Presenter: | Manolo Bellotto, Ph.D., Chief Strategy Officer & General Manager, Gain Therapeutics |
The poster presented at the MDS Congress in Madrid will be available on the Science & Technology section of the Company’s website at https://www.gaintherapeutics.com/science-technology/posters.html, following the presentation.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.
Investor & Media Contact:
Noor Pahlavi
Argot Partners
(212) 600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.20 |
| Daily Change: | 0.09 4.27 |
| Daily Volume: | 250,123 |
| Market Cap: | US$58.370M |
March 06, 2025 December 23, 2024 December 11, 2024 November 14, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
